European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 

Webcasts - Sunday 29 August 2010

ESC Congress 2010 recorded presentations

Please find here below a list of webcasts from ESC Congress 2010. Thank you to the presenters who have shared their presentations with us!

PresentationSpeakerTopicDate
Cardiac resynchronisation therapy: non responders or non progressors?Don't select the wrong patient.Maurizio Gasparini (IT)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Cardiac resynchronisation therapy: non responders or non progressors?Is lead placement a real issue?Ignacio Fernandez Lozano (ES)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Cardiac resynchronisation therapy: non responders or non progressors?Don't forget to optimise the device programming.Ali Oto (Turkey)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Cardiac resynchronisation therapy: non responders or non progressors?What is going to be next?Christophe Leclercq (FR)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Syncope in cardiology practiceAn analysis of pathophysiologies.Richard Sutton (UK)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Syncope in cardiology practiceSyncope evaluation: the role of syncope clinics.Michele Brignole (IT)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Syncope in cardiology practiceSyncope in patients without heart disease.Angel Moya I Mitjans (ES)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Syncope in cardiology practiceFalls in the elderly. Diagnostic and therapeutic approach.Stylianos Tzeis (GR)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Atrial fibrillation ablation. Optimal approaches in 2010Patients with paroxysmal atrial fibrillation.Eric N Prystowsky (US)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Atrial fibrillation ablation. Optimal approaches in 2010Patients with persistent/permanent atrial fibrillation.Carlo Pappone (IT)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Atrial fibrillation ablation. Optimal approaches in 2010Repeat procedures: the best approach.Gerhard Hindricks (DE)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Atrial fibrillation ablation. Optimal approaches in 2010Surgical approach to paroxysmal/persistent atrial fibrillation.Ralph J Damiano (US)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
The new ESC GuidelinesAtrial fibrillation.John Camm (UK)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Cardiac resynchronisation therapy: optimising patient selection with imagingAssessing mechanical dyssynchrony: echo is still alive!!!Erwan Donal (FR)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
Cardiac resynchronisation therapy: optimising patient selection with imagingDo not forget the coronary sinus anatomy.Christopher Piorkowski (DE)Arrhythmias / Pacing / Resynchronisation29 Aug 2010
The new ESC GuidelinesMyocardial revascularisation (ESC/EACTS).William Wijns (BE)Cardiovascular surgery29 Aug 2010
Revascularisation in coronary artery disease in 2010Multivessel and left main disease: indications for surgical and percutaneous intervention.William Wijns (BE)Cardiovascular surgery29 Aug 2010
Revascularisation in coronary artery disease in 2010Ways to improve coronary artery bypass grafting outcomes.Volkmar Falk (CH)Cardiovascular surgery29 Aug 2010
Revascularisation in coronary artery disease in 2010Peri-operative pharmacotherapy in high-risk unstable syndromes.Jean-Pierre Bassand (FR)Cardiovascular surgery29 Aug 2010
Revascularisation in coronary artery disease in 2010Prognostic impact of bleeding and transfusion.Lucia Torracca (IT)Cardiovascular surgery29 Aug 2010
The new ESC GuidelinesGrown-up congenital heart disease.Helmut Baumgartner (DE)Congenital heart disease / Pediatric cardiology29 Aug 2010
Management of sources of embolism: the role of echocardiographyThe neurologist's point of view.Jose Manuel Ferro (PT)Echocardiography / Doppler29 Aug 2010
Management of sources of embolism: the role of echocardiographyPermanent foramen ovale: when to close?Pierre Amarenco (FR)Echocardiography / Doppler29 Aug 2010
Management of sources of embolism: the role of echocardiographyAtherosclerosis of the aorta.Arturo Evangelista Masip (ES)Echocardiography / Doppler29 Aug 2010
Hot Line I - Heart failure and left ventricular dysfunctionThe STAR Heart Study: the acute and long-term effect of intracoronary stem cell transplantation in 191 patients with chronic heart failureBodo-Eckehard Strauer (DE)Heart failure / LV dysfunction29 Aug 2010
Hot Line I - Heart failure and left ventricular dysfunctionDiscussant: The STAR Heart Study: the acute and long-term effect of intracoronary stem cell transplantation in 191 patients with chronic heart failureFrancisco Fernandez-Aviles (ES)Heart failure / LV dysfunction29 Aug 2010
Hot Line I - Heart failure and left ventricular dysfunctionPEARL HF: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, multiple-dose study to evaluate the effects of RLY5016 in heart failure patientsBertram Pitt (US)Heart failure / LV dysfunction29 Aug 2010
Hot Line I - Heart failure and left ventricular dysfunctionDiscussant: PEARL HF: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, multiple-dose study to evaluate the effects of RLY5016 in heart failure patientsHenry J Dargie (UK)Heart failure / LV dysfunction29 Aug 2010
Hot Line I - Heart failure and left ventricular dysfunctionDiscussant: SHIFT: Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunctionInder Anand (US)Heart failure / LV dysfunction29 Aug 2010
Meet the Trialist I - SHIFTSHIFT: Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunctionMichel Komajda (FR)Heart failure / LV dysfunction29 Aug 2010
The new ESC Guidelines2010 focused update of ESC Guidelines on device therapy in heart failure.Kenneth Dickstein (NO)Heart failure / LV dysfunction29 Aug 2010
Management of acute heart failureAcutely decompensated chronic ischaemic heart failure with pulmonary congestion.Marco Metra (IT)Heart failure / LV dysfunction29 Aug 2010
Management of acute heart failureAcute heart failure with hypotension and renal dysfunction.Alexandre Mebazaa (FR)Heart failure / LV dysfunction29 Aug 2010
Management of acute heart failureWhat do the Guidelines say?Jose Lopez-Sendon (ES)Heart failure / LV dysfunction29 Aug 2010
Hypertension guidelines - are there global differences and are they important?The view of the British Hypertension Society.Adrian Jb Brady (UK)Hypertension29 Aug 2010
Hypertension guidelines - are there global differences and are they important?Asian Pacific Society - the view from down under.John P Chalmers (AU)Hypertension29 Aug 2010
Drug-eluting stents: from revolution to evolutionCurrent limitations.Eric Eeckhout (CH)Interventional cardiology29 Aug 2010
Drug-eluting stents: from revolution to evolutionOptimal antiplatelet therapy.Manel Sabate Tenas (ES)Interventional cardiology29 Aug 2010
Drug-eluting stents: from revolution to evolutionCost-effectiveness.David J Cohen (US)Interventional cardiology29 Aug 2010
Drug-eluting stents: from revolution to evolutionNew drug-eluting stents.Alexandre Abizaid (BR)Interventional cardiology29 Aug 2010
Clinical Trial Update IISAR TEST 4: Two-year Clinical Outcomes from a Randomized Trial of Biodegradable Polymer Drug-Eluting Stents Versus Permanent Polymer Cypher and Xience Drug-Eluting StentsRobert Byrne (DE)Interventional cardiology29 Aug 2010
Clinical Trial Update IDiscussant: ISAR TEST 4: Two-year Clinical Outcomes from a Randomized Trial of Biodegradable Polymer Drug-Eluting Stents Versus Permanent Polymer Cypher and Xience Drug-Eluting StentsJean Marco (FR)Interventional cardiology29 Aug 2010
Therapeutic options in chronic refractory anginaScale of the problem.Anselm Kai Gitt (DE)Ischaemia / ACS / infarction29 Aug 2010
Therapeutic options in chronic refractory anginaSpinal cord stimulation.Mats Borjesson (SE)Ischaemia / ACS / infarction29 Aug 2010
Therapeutic options in chronic refractory anginaEnhanced external counterpulsation.Ozlem Soran (US)Ischaemia / ACS / infarction29 Aug 2010
Therapeutic options in chronic refractory anginaCan interventional cardiologists do better?Jens Kastrup (DK)Ischaemia / ACS / infarction29 Aug 2010
Therapeutic challenges in octogenarians with ischaemic heart diseasePrevention.Dan Gaita (RO)Ischaemia / ACS / infarction29 Aug 2010
Therapeutic challenges in octogenarians with ischaemic heart diseaseFibrinolysis.Hector Bueno (ES)Ischaemia / ACS / infarction29 Aug 2010
Therapeutic challenges in octogenarians with ischaemic heart diseasePercutaneous interventions.Nicolas Danchin (FR)Ischaemia / ACS / infarction29 Aug 2010
Hot Line I - Heart failure and left ventricular dysfunctionHEBE III: A single dose of erythropoietin in ST-elevation myocardial infarctionAdriaan Voors (NL)Ischaemia / ACS / infarction29 Aug 2010
Hot Line I - Heart failure and left ventricular dysfunctionDiscussant: HEBE III: A single dose of erythropoietin in ST-elevation myocardial infarctionPiotr Ponikowski (PL)Ischaemia / ACS / infarction29 Aug 2010
Clinical Trial Update IMULTI STRATEGY: 3-year Follow-up of the Comparison of Angioplasty with Infusion of Tirofiban or Abciximab and with Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial InfarctionMarco Valgimigli (IT)Ischaemia / ACS / infarction29 Aug 2010
Clinical Trial Update IPLATO genetic substudy: Impact of CYP2C19 and ABCB1 single nucleotide polymorphisms (SNPs) on outcomes with ticagrelor and clopidogrel in acute coronary syndrome - a PLATO genetic substudyLars Wallentin (SE)Ischaemia / ACS / infarction29 Aug 2010
Clinical Trial Update IDiscussant: PLATO genetic substrudy: Impact of CYP2C19 and ABCB1 single nucleotide polymorphisms (SNPs) on outcomes with ticagrelor and clopidogrel in acute coronary syndrome - a PLATO genetic substudyKurt Huber (AT)Ischaemia / ACS / infarction29 Aug 2010
Meet the Trialist II - HEBE IIIHEBE III: A Single Dose of Erythropoietin in ST-elevation Myocardial InfarctionAdriaan Voors (NL)Ischaemia / ACS / infarction29 Aug 2010
Innovations in imaging of coronary heart diseaseNew developments in myocardial perfusion imaging.Roxy Senior (UK)Ischaemia / ACS / infarction29 Aug 2010
Anti-thrombotic therapy in acute coronary syndromes - difficult situationsPretreatment in STEMI.Christian Hamm (DE)Ischaemia / ACS / infarction29 Aug 2010
Anti-thrombotic therapy in acute coronary syndromes - difficult situationsNSTEMI - management strategy in a patient with an increased bleeding risk.David Erlinge (SE)Ischaemia / ACS / infarction29 Aug 2010
Anti-thrombotic therapy in acute coronary syndromes - difficult situationsWhat do the Guidelines say?Steen Dalby Kristensen (DK)Ischaemia / ACS / infarction29 Aug 2010
Infectious myocarditis and pericarditisViral myocarditis/pericarditis: pathogenesis.Alida Lp Caforio (IT)Myocardial-Pericardial disease29 Aug 2010
Infectious myocarditis and pericarditisHow to diagnose viral infection of the heart and pericardium.Sabine Pankuweit (DE)Myocardial-Pericardial disease29 Aug 2010
Infectious myocarditis and pericarditisHow to treat viral myocarditis.Uwe Kuehl (DE)Myocardial-Pericardial disease29 Aug 2010
Infectious myocarditis and pericarditisBacterial infections of the myocardium and pericardium.Petar Seferovic (Serbia)Myocardial-Pericardial disease29 Aug 2010
Innovations in imaging of coronary heart diseaseRole of magnetic resonance imaging in the acute myocardial infarction.Massimo Lombardi (IT)Nuclear cardiology, CMR & CT29 Aug 2010
Assessment of myocardial viabilityCases 1.Hans-Marc Siebelink (NL)Nuclear cardiology, CMR & CT29 Aug 2010
Assessment of myocardial viabilityCases 2.Heikki Ukkonen (FI)Nuclear cardiology, CMR & CT29 Aug 2010
Clinical Trial Update IDiscussant: CURE ACTIVE: Efficacy and Safety of Clopidogrel compared with Placebo according to CYP2C19 Genotype in over 6000 patients with Non-ST-elevation Acute Coronary Syndromes (CURE trial) and atrial fibrillation (ACTIVE trial)Robert M Califf (US)Pharmacology and pharmacotherapy29 Aug 2010
Therapeutic challenges in octogenarians with ischaemic heart diseaseAntiplatelet/anticoagulant treatment and risk of bleeding.Freek Verheugt (NL)Prevention and rehabilitation29 Aug 2010
Hot Line I - Heart failure and left ventricular dysfunctionDiscussant: ALPHA OMEGA: Effect of low doses of n-3 fatty acids on cardiovascular diseases in post-MI patientsLuigi Tavazzi (IT)Prevention and rehabilitation29 Aug 2010
Update on the management of dyslipidemiasGlobal cardiovascular risk: the role of lipids.Ian Graham (Ireland)Prevention and rehabilitation29 Aug 2010
Update on the management of dyslipidemiasPlasma lipid control in Europe: recent data.David Allan Wood (UK)Prevention and rehabilitation29 Aug 2010
Update on the management of dyslipidemiasCardiovascular benefit of low-density lipoprotein lowering.Terje Pedersen (NO)Prevention and rehabilitation29 Aug 2010
Update on the management of dyslipidemiasHigh-density lipoprotein and cardiovascular risk.John Chapman (FR)Prevention and rehabilitation29 Aug 2010
Update on the management of dyslipidemiasTriglycerides and cardiovascular risk.Marja-Riitta Taskinen (FI)Prevention and rehabilitation29 Aug 2010
Acute pulmonary embolism - 2010ESC Guidelines versus real-life diagnosis of acute pulmonary embolism - data from ZATPOL Registry.Adam Torbicki (PL)Pulmonary circulation29 Aug 2010
Acute pulmonary embolism - 2010Largest ever - lessons from RIETE Registry of venous thromboembolism.Manuel Monreal Bosch (ES)Pulmonary circulation29 Aug 2010
Acute pulmonary embolism - 2010PEITHO - the hope for 'intermediate-risk' patients.Stavros V Konstantinides (GR)Pulmonary circulation29 Aug 2010
Acute pulmonary embolism - 2010ESC Guidelines on management of acute pulmonary embolism - is an update needed?Arnaud Perrier (CH)Pulmonary circulation29 Aug 2010
Difficult aspects of aortic stenosisPrognosis of patients with mild to moderate aortic stenosis.Anne Bjorhovde Rossebo (NO)Valvular disease29 Aug 2010
Difficult aspects of aortic stenosisChallenges in assessing aortic stenosis.Catherine M Otto (US)Valvular disease29 Aug 2010
Difficult aspects of aortic stenosisLow gradient severe aortic stenosis with normal left-ventricular ejection fraction: a disturbing clinical entity.Jean-Luc Monin (FR)Valvular disease29 Aug 2010
Difficult aspects of aortic stenosisTranscatheter aortic valve implantation update 2010.Thierry Lefevre (FR)Valvular disease29 Aug 2010
Endocarditis: what's new in the guidelines?Prevention and patient education.Bernard David Prendergast (UK)Valvular disease29 Aug 2010
Endocarditis: what's new in the guidelines?When to operate and how.Manuel J Antunes (PT)Valvular disease29 Aug 2010
Endocarditis: what's new in the guidelines?Neurological problems in patients with endocarditis.Jose Alberto San Roman Calvar (ES)Valvular disease29 Aug 2010
Clinical Trial Update IEVOLUTION: Clinical EValuation Of the Edwards Lifesciences percUTaneous mItral annulOplasty system for the treatment of mitral regurgitatioNJan Harnek (SE)Valvular disease29 Aug 2010
Clinical Trial Update IDiscussant: EVOLUTION: Clinical EValuation Of the Edwards Lifesciences percUTaneous mItral annulOplasty system for the treatment of mitral regurgitatioNManuel J Antunes (PT)Valvular disease29 Aug 2010
Clinical Trial Update ISOURCE REGISTRY TAVI: Development of a risk score for transcatheter aortic valve implantation: 1-year outcomes from over 1,000 patients in the source registryOlaf Wendler (UK)Valvular disease29 Aug 2010
Clinical Trial Update IDiscussant: SOURCE REGISTRY TAVI: Development of a risk score for transcatheter aortic valve implantation: 1-year outcomes from over 1,000 patients in the source registryGerhard Schuler (DE)Valvular disease29 Aug 2010
Collateral damage to the heart: effects of novel molecular therapies in oncology and ophtalmologyConventional chemotherapy and cardiac side effects.Michael Hallek (DE)Vascular biology29 Aug 2010
Collateral damage to the heart: effects of novel molecular therapies in oncology and ophtalmologyAnti-angiogenesis for wet age-related macular degeneration and diabetic retinopathy.Nicolas Leveziel (FR)Vascular biology29 Aug 2010
Collateral damage to the heart: effects of novel molecular therapies in oncology and ophtalmologyInhibition of tumour angiogenesis and cardiovascular side effects.Renu Virmani (US)Vascular biology29 Aug 2010
Meet the Trialist I - SHIFTSHIFT: Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunctionIan Ford (UK) 29 Aug 2010
The new ESC GuidelinesMyocardial revascularisation (ESC/EACTS).Philippe H Kolh (BE) 29 Aug 2010



 
Highlight On